Clinical Analysis: Mrs. Sushma Sanjeev Chintal, 66F

Patient Summary at a Glance

Key Question 1: Why Was a Bisphosphonate Never Given?

• Multiple vertebral fractures
• 7 doses of denosumab completed with the last dose April 2026
• Teriparatide now discontinued (last dose June 2026)
• One dose of romosozumab taken

Key Question 2: Cause of Repeated Hyponatremia - NOT Just SIADH

CRITICAL RED FLAG: Her 8 AM Cortisol is 41.63 nmol/L (approximately 1.5 mcg/dL)

• History of pulmonary TB (1993): TB is a classic cause of primary adrenal insufficiency (Addison's disease) via adrenal calcification/destruction, even decades later
• Long-term tolvaptan use
• Denosumab has rare associations with hypocalcemia-driven secondary HPT (PTH now elevated at 119)

Additional supporting evidence for AI:

• Low uric acid (1.56 mg/dL) - hypouricemia is seen in SIADH but also in adrenal insufficiency
• Weakness, low power in lower limbs (3/5) - can be feature of chronic AI
• The fact that hyponatremia keeps recurring despite tolvaptan treatment suggests a persistent physiological driver (not just random SIADH)
• PTH elevation to 119 and low calcium (8.32) - cortisol deficiency impairs calcium metabolism

1. Send plasma ACTH (ideally paired with the cortisol already done)
2. Short Synacthen (ACTH stimulation) test - this is the gold standard
3. Adrenal CT to look for TB sequelae (calcification, atrophy)
4. If AI confirmed: hydrocortisone replacement will likely resolve the hyponatremia

Key Question 3: What to Give for Osteoporosis Going Forward?

Current Status - Extremely Concerning Sequence

Recommended Osteoporosis Management Plan:

• Rationale: Denosumab was stopped in April 2026. The rebound bone loss window peaks at 6-18 months. She is already 3.5 months post last dose. Zoledronate given now will occupy the skeleton's binding sites and prevent the rapid osteoclast-driven resorption that follows denosumab discontinuation
• IV route avoids all GI concerns
• Renal function: Check GFR first - zoledronate is contraindicated if GFR <35 mL/min. Her creatinine is not provided; this must be checked
• Pre-treat with adequate hydration and ensure vitamin D >30 ng/mL (currently 22.1 - supplement first or simultaneously)
• Give calcium supplementation (already on Shelcal XT)

• She needs to complete the 12-dose course (currently only 1 dose taken)
• Must be followed by an antiresorptive (bisphosphonate or denosumab) when complete
• Caution: Romosozumab is associated with increased cardiovascular events - her 2D Echo shows EF 60% (preserved) which is reassuring, but her CV risk must be formally assessed

Key Question 4: Why is Gastrin and Chromogranin A High with a Normal DOTATATE PET?

Timeline is Diagnostic:

• Feb 2026: Gastrin 47.1, CgA 73.74 - NORMAL
• April 2026: Gastrin 931, CgA 1109 - MASSIVELY ELEVATED

Most Likely Cause: Proton Pump Inhibitors (PPIs)

1. PPIs inhibit gastric parietal cell H+/K+-ATPase, reducing gastric acid
2. Low acid stimulates G-cells to release more gastrin (a negative feedback loop is broken)
3. Sustained hypergastrinemia causes enterochromaffin-like (ECL) cell hyperplasia
4. ECL cells release chromogranin A in proportion to their mass/stimulation
5. Result: Both gastrin and CgA rise dramatically - without a tumor being present

• She has Grade 1 esophageal candidiasis (Jan 2026) - she was likely started on/continuing a PPI or H2 blocker for this and for her antral gastritis
• Antral gastritis (May 2024) - a classic indication for PPI therapy
• The dramatic rise from Feb to April 2026 coincides exactly with the period when esophageal candidiasis was treated and GI symptoms were active (when PPI use would increase)

• Chronic atrophic gastritis (she has antral gastritis) independently elevates both markers
• Low cortisol / adrenal insufficiency - stress response can elevate CgA
• Cardiac disease can elevate CgA (though EF is preserved here)
• Renal impairment (check GFR - not documented)

What To Do:

1. Stop PPIs (or reduce to minimum necessary) for at least 14 days
2. Retest gastrin and CgA after PPI cessation - if levels normalize (as in Feb 2026), diagnosis is confirmed false positive
3. Do NOT pursue further invasive workup for NET unless levels remain elevated off PPIs
4. Her Feb 2026 values (Gastrin 47, CgA 73) are essentially normal - this strongly supports PPI effect as the explanation
5. Urinary 5-HIAA was 10.74 mg/24h (borderline - normal <8 mg/24h, but dietary factors like tomatoes, nuts, bananas can elevate this; needs repeat in fasted dietary-restricted state)

Summary Action Points (Prioritized)

One Overarching Concern

• Persistent hyponatremia (via ADH non-suppression)
• Weakness and fatigue
• Bone loss (cortisol deficiency impairs bone metabolism)
• Low uric acid
• Chronically elevated CgA (stress-related ECL stimulation)

Clinical Analysis - Mrs. Sushma Sanjeev Chintal (66F)

Q1: Why Was a Bisphosphonate Never Given?

• Grade 1 esophageal candidiasis (Jan 2026)
• Antral gastritis (May 2024)
• Multiple admissions for abdominal pain Oral bisphosphonates (alendronate/risedronate) require fasting ingestion with large water volumes, strict upright posture, and carry significant esophagitis risk - all contraindicated in her GI profile.

Q2: Cause of Recurrent Hyponatremia - The Missed Diagnosis

1. Plasma ACTH level (paired with cortisol)
2. Short Synacthen (ACTH stimulation) test - gold standard
3. Adrenal CT - look for calcification, atrophy from old TB
4. If confirmed AI: Hydrocortisone replacement will likely resolve the hyponatremia, allowing tolvaptan to be tapered and stopped

Q3: What to Give for Osteoporosis to Prevent Future Fractures?

• Check GFR first (contraindicated if <35 mL/min)
• Correct vitamin D to >30 ng/mL before/alongside (currently D3 22.1 - give 60,000 IU weekly cholecalciferol x 8-12 weeks)
• This bridges the denosumab discontinuation and prevents catastrophic rebound fractures
• A 2026 meta-analysis (PMID 41105226) and ACP 2023 guidelines endorse bisphosphonates as first-line and as essential post-denosumab bridging therapy

• Most potent anabolic agent; 210 mg SC monthly, 12 doses total (she has had only 1)
• EF 60% preserved - reassuring, but formal CV risk assessment needed given romosozumab's boxed warning for cardiovascular events
• After 12 doses, transition to antiresorptive (zoledronate annually)

• D3 22.1 - insufficient; target >40 ng/mL for osteoporosis management
• PTH 119 - secondary hyperparathyroidism driven by low D3/low calcium; should normalize with D3 correction
• Shelcal XT (calcium + D3) - continue

Q4: Why is Gastrin + CgA High with Normal DOTATATE PET?

• February 9, 2026: Gastrin 47.1 pg/mL (normal), CgA 73.74 (normal)
• April 2026: Gastrin 931, CgA 1109 - a 20-fold rise in 6 weeks

• Esophageal candidiasis (Jan 2026) - PPI likely started or escalated
• Antral gastritis - ongoing PPI indication
• The rise from Feb to April exactly matches when PPI use would have been increased for GI complaints

• Chronic atrophic gastritis (she has gastritis)
• Adrenal insufficiency (stress-state)
• Renal impairment (GFR unknown - needs checking)
• Heart failure (EF preserved - less likely)

1. Stop or hold PPIs for minimum 14 days
2. Retest CgA and gastrin in fasting state after PPI cessation
3. If they return toward her Feb 2026 normal values, false-positive is confirmed - no further NET workup needed
4. Borderline urinary 5-HIAA (10.74, normal <8 mg/24h) - repeat under strict dietary restrictions (no bananas, tomatoes, nuts, avocado, walnuts 48h before collection) before concluding it is truly elevated

Unified Clinical Picture

• Low cortisol → persistent ADH → recurrent hyponatremia misread as SIADH
• Cortisol deficiency → impaired osteoblast function → worsened bone loss
• Stress physiology from untreated AI → elevated CgA
• Frailty and weakness attributed to osteoporosis and neuropathy may partly be hypocortisolism